Trial Profile
A Phase 1, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RM 493 Administered to Healthy Obese Non-diabetic Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Setmelanotide (Primary)
- Indications Diabetes mellitus; Obesity
- Focus Adverse reactions
- Sponsors Rhythm Pharmaceuticals
- 04 Jan 2013 Status changed from recruiting to completed based on information reported in a Rhythm media release.
- 19 Jun 2012 New trial record